Cargando…

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms

OBJECTIVE: The aim of this study was to determine the clinical meaningfulness of TX-001HR in reducing moderate to severe vasomotor symptoms (VMS) in menopausal women with a uterus. METHODS: In the REPLENISH study (NCT01942668), women with moderate to severe hot flushes (≥7/d or ≥50/wk) were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantine, Ginger D., Revicki, Dennis A., Kagan, Risa, Simon, James A., Graham, Shelli, Bernick, Brian, Mirkin, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott-Raven Publishers 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493698/ https://www.ncbi.nlm.nih.gov/pubmed/30516713 http://dx.doi.org/10.1097/GME.0000000000001261

Ejemplares similares

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
por: Constantine, Ginger D., et al.
Publicado: (2020)

SAT-001 Clinically Meaningful Effects of E2/P4 Oral Capsule in Treating Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
por: Kagan, Risa, et al.
Publicado: (2018)

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
por: Kaunitz, Andrew M., et al.
Publicado: (2020)

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
por: Simon, James A., et al.
Publicado: (2019)

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
por: Lobo, Rogerio A., et al.
Publicado: (2019)

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms
por: Santoro, Nanette, et al.
Publicado: (2019)

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)(∗)
por: Mirkin, Sebastian, et al.
Publicado: (2020)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR
por: Kingsberg, Sheryl A., et al.
Publicado: (2017)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone
por: Mirkin, Sebastian, et al.
Publicado: (2019)

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women
por: Constantine, Ginger D., et al.
Publicado: (2017)

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol
por: Archer, David F., et al.
Publicado: (2017)

SAT-LB003 Nonsmokers Benefit from Lower Doses of an Estradiol/Progesterone Combination: Results of the REPLENISH Trial
por: Constantine, Ginger, et al.
Publicado: (2019)

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review
por: Constantine, Ginger D., et al.
Publicado: (2019)

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial
por: Simon, James A., et al.
Publicado: (2017)

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial
por: Liu, James H., et al.
Publicado: (2020)

Systemic estradiol levels with low-dose vaginal estrogens
por: Santen, Richard J., et al.
Publicado: (2019)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial
por: Black, Denise R., et al.
Publicado: (2020)

Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy
por: Pickar, James H., et al.
Publicado: (2015)

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries
por: Constantine, Ginger D, et al.
Publicado: (2016)

Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert
por: Mirkin, Sebastian, et al.
Publicado: (2021)

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies
por: Stanczyk, Frank Z., et al.
Publicado: (2019)

SAT-239 Bioidentical Estradiol and Progesterone Improved Hot Flushes, Night Sweats and Sweating
por: Liu, James, et al.
Publicado: (2019)

Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule
por: Pickar, J. H., et al.
Publicado: (2016)

Estrogen Protects Vasomotor Functions in Rats During Catecholamine Stress
por: Zhang, Lin, et al.
Publicado: (2021)

Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
por: Vitolins, Mara Z, et al.
Publicado: (2010)

MON-006 Progesterone Receptor Expression in Endometrial Biopsies After 12 Weeks of Exposure to A 4-µg E2 Softgel Vaginal Insert or Placebo
por: Simon, James A, et al.
Publicado: (2020)

The temporal reliability of serum estrogens, progesterone, gonadotropins, SHBG and urinary estrogen and progesterone metabolites in premenopausal women
por: Williams, Andrew E, et al.
Publicado: (2002)

A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol
por: Pickar, James H., et al.
Publicado: (2016)

Estrogen, Progesterone and Epithelial Ovarian Cancer
por: Ho, Shuk-Mei
Publicado: (2003)

The Impact of Progesterone and Estrogen on the Tooth Mobility
por: Peruga, Małgorzata, et al.
Publicado: (2023)

INTERACTION OF ESTROGEN AND PROGESTERONE IN CHICK OVIDUCT DEVELOPMENT : II. Effects of Estrogen and Progesterone on Tubular Gland Cell Function
por: Oka, Takami, et al.
Publicado: (1969)

Vasomotor Tumentia
por: Goodall, Alexander
Publicado: (1928)

Physical characteristics and properties of estradiol softgel vaginal inserts
por: Simon, James A., et al.
Publicado: (2019)

SAT001 Membrane Progesterone Receptors Induce Glycogenolysis In Uterine Epithelial Cells
por: Berg, Malia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o0oli0hs1trea9pv2co0fv5274